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S yncope, a transient loss of consciousness, is a commonclinical problem. The most common causes of syncope are
cardiovascular in origin and are associated with a high rate of
mortality in patients with underlying heart disease, transient myo-
cardial ischemia, and other less common cardiac abnormalities.(1)
The primary purpose of the evaluation of the patient with
syncope is to determine whether the patient is at increased
risk for death. This involves identifying patients with under-
lying heart disease, myocardial ischemia, Wolff-Parkinson-
White syndrome, and potentially life-threatening genetic
diseases such as long-QT syndrome (LQTS), Brugada syn-
drome, and catecholaminergic polymorphic ventricular
tachycardia. If these diagnoses can be excluded, the goal then
becomes identification of the cause of syncope in an attempt
to improve the quality of the patient’s life and to prevent
injury to the patient or others. The purpose of this statement
is to summarize the data that direct the evaluation of the
patient with syncope (Figure 1).
General Evaluation
In the general population, the most common cause of syncope
is neurocardiogenic, followed by primary arrhythmias. Other
The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside
relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required
to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.
This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on August 3, 2005. A single reprint
is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX
75231-4596. Ask for reprint No. 71-0342. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000
or more copies, call 410-528-4121, fax 410-528-4264, or e-mail kgray@lww.com. To make photocopies for personal or educational use, call the
Copyright Clearance Center, 978-750-8400.
Expert peer review of AHA Scientific Statements is conducted at the AHA National Center. For more on AHA statements and guidelines development,
visit http://www.americanheart.org/presenter.jhtml?identifier3023366.
This article has been copublished in Circulation.
J Am Coll Cardiol 2006;47:473–84.
© 2006 American Heart Association, Inc., and the American College of Cardiology Foundation.
doi:10.1016/j.jacc.2005.12.019
General Evaluation........................................................... 473
History and Physical Examination ................................. 474
ECG, Echocardiogram, and Ischemia Evaluation........... 475
Syncope in the Patient With a Normal Evaluation ....... 475
Syncope in the Patient With Coronary Artery Disease....... 476
Nonischemic Dilated Cardiomyopathy ................................. 477
Syncope in Other Forms of Structural Heart Disease......... 477
Syncope Resulting From Inherited Cardiac Ion Channel
Abnormalities ..................................................................... 478
Evaluation of the Pediatric Patient With Syncope............... 478
Special Considerations in the Elderly ................................... 480
Neurological Evaluation ......................................................... 480
Conclusions.............................................................................. 481
Writing Group Disclosures .................................................... 481
Reviewers’ Disclosures .......................................................... 482
References................................................................................ 483
AHA/ACCF Scientific Statement
names for neurocardiogenic syncope include neurally medi-
ated, vasodepressor, and vasovagal syncope. The causes of
syncope are highly age dependent.(2) Pediatric and young
patients are most likely to have neurocardiogenic syncope,
conversion reactions (psychiatric causes), and primary ar-
rhythmic causes such as the LQTS and Wolff-Parkinson-
White syndrome. In middle age, neurocardiogenic syncope
remains the most frequent cause of syncope. Syncope related
to other forms of neurocardiogenic syncope such as degluti-
tion, micturition, defecation, and cough, as well as orthostasis
and panic disorders, is more common in the middle-aged or
elderly patients than in younger patients. In contrast to
younger patients, elderly patients have a higher frequency of
syncope caused by obstructions to cardiac output, eg, aortic
stenosis and pulmonary embolus, and arrhythmias resulting
from underlying heart disease.
History and Physical Examination
The approach to the patient with syncope begins with a
meticulous history.(1,3,4) In most patients, the cause of
syncope can be determined with great accuracy from a careful
history and physical examination, although the mechanism of
syncope remains unexplained in 40% of episodes.(3) The
process of evaluating the history, physical examination, and
ECG should also include assessment of the medication list for
agents associated with proarrhythmia, eg, Class IA and IC
antiarrhythmic drugs.
Various aspects of the history help to establish the diag-
nosis. The observations of onlookers are important. The
occurrence of tonic-clonic, seizurelike activity is associated
with both cardiac and neurological causes of syncope.(5)
Episodes of neurocardiogenic syncope are typically associ-
ated with postepisode fatigue or weakness, whereas the
absence of a prodrome is consistent with cardiac arrhythmia
or, less commonly, a central neurodegenerative disorder with
autonomic failure such as Parkinson disease.(6) Auras, pre-
monitions, postictal confusion, and focal neurological signs
and symptoms suggest a neurological cause. Transient ische-
mic attacks rarely result in syncope. However, patients with
Figure 1. Flow chart for the diagnostic approach to the patient with syncope.
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basilar artery or severe bilateral carotid artery disease may
have syncope that usually is associated with focal neurolog-
ical symptoms. A history of myocardial infarction with or
without left ventricular dysfunction or repaired congenital
heart disease raises the possibility of ventricular arrhythmias.
A history of head trauma in a younger person without
underlying heart disease may suggest a neurological origin,
whereas syncope precipitated by neck turning, particularly in
the elderly, raises the possibility of carotid sinus hypersensi-
tivity. This can be assessed at the bedside with carotid sinus
massage in patients in the supine and/or upright positions.
However, this test should not be performed in patients with a
recent transient ischemic attack or stroke, or ipsilateral to
significant carotid artery stenosis or carotid artery bruit. The
patient should be asked specifically if there is a positive
family history for unexpected sudden cardiac death.
The history is also useful for identifying aggravating and
alleviating factors. For example, the addition of a new drug,
especially an antiarrhythmic or antihypertensive agent, raises
the possibilities of proarrhythmia and orthostasis, respec-
tively. In the elderly, phenothiazine and tricyclic drugs
predispose to orthostasis. The possible role of over-the-
counter medications and supplements, eg, ephedra-containing
preparations, should be addressed.
During the evaluation of syncope, a careful physical
examination is second only to the history. Orthostatic hypo-
tension, autonomic dysfunction, and sometimes organic heart
disease can be identified by measuring blood pressure and
pulse rate in the upper and lower extremities and in the supine
and upright positions. Carotid bruits raise the question of
impaired cerebral blood flow and underlying coronary artery
disease. The physical examination can also suggest the
presence of pulmonary hypertension, left ventricular dysfunc-
tion, valvular heart disease, or other forms of organic heart
disease. Abnormalities of cognition and speech, visual fields,
motor strength, sensation, tremor, and gait disturbance sug-
gest an underlying neurological disorder.
ECG, Echocardiogram, and Ischemia Evaluation
The ECG provides important information about the rhythm
and atrioventricular (AV) conduction. Sinus bradycardia, a
prolonged PR interval, or bundle-branch block raises the
possibility of symptomatic sick sinus syndrome or intermit-
tent complete AV block. Examination of the QRS complex
may identify the presence of a delta wave, signifying the
presence of an accessory pathway and Wolff-Parkinson-
White syndrome. Genetic diseases of cardiac channels such
as the LQTS and Brugada syndrome can be identified on the
surface ECG and can cause syncope and life-threatening
ventricular arrhythmias.(7) The ECG may suggest arrhyth-
mogenic right ventricular dysplasia/cardiomyopathy (ARVD/
C), in which case a cardiac MRI may aid in establishing the
diagnosis. Ventricular ectopy or nonsustained ventricular
tachycardia in a patient with underlying heart disease raises
the possibility of an arrhythmic origin of syncope.
An echocardiogram is a helpful screening test if the
history, physical examination, and ECG do not provide a
diagnosis or if underlying heart disease is suspected. The
echocardiogram is an excellent way to identify underlying
heart disease, including valvular disease. It can also suggest
pulmonary embolism if pulmonary hypertension or right
ventricular enlargement is present. The most common cause
of sudden death in athletes is hypertrophic cardiomyopathy,
which is readily indicated by echocardiography.(8) The
second most common cause of sudden death in the young is
the presence of an anomalous coronary artery.(8) In young
and thin individuals, the coronary ostia may be identified by
a transthoracic echocardiogram, and if not visualized, the
presence of an anomalous coronary artery may be further
evaluated with a transesophageal echocardiogram, cardiac
MRI or CT, or other imaging modality.
An evaluation for ischemia is appropriate in patients at risk
for or with a history of coronary artery disease. Exercise
testing should be performed in the patient with unexplained
syncope, especially if the episode was exercise related.
Exercise testing provides the opportunity to monitor pulse
and blood pressure. In patients less than 40 years of age, a
drop in blood pressure or failure of blood pressure to rise with
exercise raises the question of hypertrophic obstructive car-
diomyopathy or left main coronary artery disease(9); in the
elderly patient, it may be a manifestation of autonomic
failure. Exercise testing also screens for catecholaminergic
polymorphic ventricular tachycardia.
Syncope in the Patient With a Normal Evaluation
In the absence of underlying heart disease, syncope is not
associated with excess mortality. The main risk is related to
physical harm that may occur if the patient has recurrent
syncope. In this setting, the intensity of the workup to
establish a diagnosis is determined by the “malignancy” of
the episode. For the purposes of this statement, a malignant
episode of syncope is defined as an episode of syncope that
occurs with little or no warning and results in a significant
injury or property damage, eg, a car accident.
When the general workup is normal, the origin of syncope
can be extremely challenging to ascertain. Although many
life-threatening clinical entities are less likely in the presence
of a normal evaluation, the possibility of neurocardiogenic
syncope, carotid sinus hypersensitivity, paroxysmal bradyar-
rhythmias, supraventricular tachycardia, ventricular
tachycardia, and myriad noncardiac causes of syncope re-
mains.(10) The gold standard for diagnosing an arrhythmic
cause of syncope is ECG documentation of the rhythm
disturbance at the time of symptoms. However, it is rare to
have documentation of the cardiac rhythm from the initial
episode of syncope.
Noninvasive ECG Monitoring
The type and duration of ambulatory ECG monitoring is
dictated by the frequency of symptoms. A Holter monitor is
appropriate for episodes that occur at least every day. Event
monitoring is ideal for episodes that occur at least once a
month. An implantable loop monitor allows the correlation of
symptoms with the cardiac rhythm in patients in whom the
symptoms are infrequent.
Traditionally, ambulatory monitoring is carried out for 24
to 48 hours with a Holter monitor. The short duration of the
recording limits the diagnostic yield. Event recorders allow
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ambulatory monitoring for 30 to 60 days. Patient triggering
stores the ECG from 1 to 4 minutes before and 30 to 60
seconds after activation. The major limitation of the device is
the complexity of its use, which results in patient errors with
acquisition and transmission of data.(11) The introduction of
continuously recording monitors that have both patient-acti-
vated and automatic triggers appears to improve the diagnos-
tic yield of event monitors.(12)
Implantable loop recorders inserted subcutaneously are
capable of recording bipolar ECG signals for approximately
14 months. The patient may use an activator to record the
rhythm at the time of symptoms, and the device automatically
records bradycardia and tachycardia. In patients with unex-
plained syncope, use of an implantable loop recorder for 1
year yielded diagnostic information in more than 90% of
patients.(12) This approach is more likely to identify the
mechanism of syncope than is a conventional approach that
uses Holter or event monitors and electrophysiological testing
and is cost-effective.(13)
Analysis of T-wave alternans with signal-averaged ECG
and assessment of heart rate variability are noninvasive
methods for identifying patients at increased risk for sudden
cardiac death. The routine use of these tools in patients with
syncope and a negative initial evaluation is not established
and currently is not indicated.
Tilt Table Test
Tilt table testing is used as an aid in establishing the diagnosis
of neurocardiogenic syncope. However, serious questions
about the sensitivity, specificity, diagnostic yield, and day-
to-day reproducibility of tilt table testing exist.(14 –17) The
reported sensitivity and specificity of tilt table testing depend
on the technique used. The sensitivity ranges from 26% to
80%, and the specificity is approximately 90%. In patients
with a negative evaluation, ie, no evidence of ischemia and a
structurally normal heart, the pretest probability that the
diagnosis is neurocardiogenic syncope is high, so head-up tilt
table testing contributes little to establishing the diagnosis.
For example, in a patient of any age with an otherwise normal
evaluation who has a negative tilt table test, the most likely
diagnosis is still neurocardiogenic syncope. In patients with a
malignant episode of syncope, it may be more important to
rule out other causes of syncope such as bradyarrhythmias,
supraventricular tachycardia, and ventricular tachycardia than
it is to perform a tilt table test. This is especially true because
the risk for recurrent syncope in the patient with a normal
cardiac evaluation and syncope is similar in patients with a
positive or negative tilt table test.
Electrophysiological Study
Electrophysiological testing involves placement of trans-
venous catheters within the heart to assess sinus node
function, AV conduction, and susceptibility to supraventric-
ular and ventricular tachycardias. In patients with a normal
evaluation for syncope, the yield of electrophysiological
testing is approximately 3%.(14) The sensitivity of electro-
physiological testing for the detection of bradyarrhythmias is
low.(15) Because of the low yield of electrophysiological
testing in patients without underlying heart disease, this test is
not routinely recommended.(16,17) However, given the low
risk of electrophysiological testing(18) and the high risk of
recurrent syncope with potential harm to the patient, the
risk-to-benefit ratio may favor electrophysiological testing in
patients with a malignant episode of syncope.
Syncope in the Patient With Coronary
Artery Disease
The risk of death in a patient with syncope and coronary
artery disease is directly proportional to the severity of left
ventricular dysfunction. In the patient with coronary artery
disease, recurrent episodes of ischemia and arrhythmia diag-
noses such as bradycardia and ventricular tachycardia should
be considered.
The major goal of the evaluation of syncope in the patient
with coronary artery disease is to identify a potentially
life-threatening diagnosis. This necessitates an evaluation for
ischemia, underlying heart disease, and arrhythmias. If these
patients require revascularization, the arrhythmia evaluation
is still needed because, when present, the substrate for
ventricular tachycardia and lethal ventricular arrhythmias is
not ameliorated by revascularization. However, ventricular
tachycardia or ventricular fibrillation that occurs in the setting
of an acute ST-segment–elevation myocardial infarction may
not require a specific arrhythmia evaluation, particularly if
the left ventricular ejection fraction is well preserved.
Electrophysiological Study
After an ischemia evaluation, the patient with coronary artery
disease and syncope should undergo electrophysiological
testing. Electrophysiological testing is a useful method to
assess sinus node function and AV conduction; however, it is
a much better test for identifying the presence of ventricular
tachyarrhythmias and the risk of death in the patient with
coronary artery disease and syncope. Independent of the left
ventricular ejection fraction, patients with syncope, coronary
artery disease, and inducible monomorphic ventricular
tachycardia during electrophysiological testing should be
treated with an implantable defibrillator.
Among patients with coronary artery disease, syncope, and
mild-to-moderate left ventricular dysfunction, ie, left ventric-
ular ejection fraction 0.35, inducible ventricular
tachycardia during electrophysiological testing is relatively
unlikely. Despite the low yield, electrophysiological testing is
appropriate in this setting because of the significant implica-
tions of inducible ventricular tachycardia. After a negative
electrophysiological test in this patient population, the eval-
uation is usually complete. However, when a definitive
diagnosis is required, then an event monitor or an implantable
loop monitor can be used.
In the interest of finding a specific diagnosis, the patient
with coronary artery disease and syncope may undergo a
diagnostic electrophysiological test if the left ventricular
ejection fraction is 0.35. However, even in the absence of
syncope, the patient with coronary artery disease and a left
ventricular ejection fraction 0.35 has a substantial survival
benefit when treated with an implantable defibrillator.(19,20)
Therefore, the patient with syncope and severe ischemic
cardiomyopathy is an appropriate candidate for an implant-
able defibrillator regardless of the result of electrophysiolog-
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ical testing.(19 –21) Comprehensive recommendations for
implantable defibrillator therapy can be found in the ACC/
AHA/NASPE 2002 guideline update for implantation of
cardiac pacemakers and antiarrhythmia devices.(21)
Nonischemic Dilated Cardiomyopathy
Syncope is associated with increased mortality among pa-
tients with nonischemic dilated cardiomyopathy
(NIDCM).(22) The likely reason for the increased mortality is
that episodes of syncope in these patients often are caused by
self-terminating episodes of ventricular tachycardia that, if
recurring, can lead to cardiac arrest. The frequency of
syncope in this group of patients is poorly defined. In the US
Carvedilol study, which evaluated patients with refractory
heart failure from any origin, 33% of patients had dizziness,
but only 0.3% of patients had syncope over a 6-month
period.(23)
The differential diagnosis of syncope in patients with
NIDCM includes bradycardia, tachycardia, orthostatic hypo-
tension, and pulmonary embolism. Although other causes of
syncope may still occur in these patients, the presence of
myocardial dysfunction increases the probability of an ar-
rhythmic origin. Vigorous ventricular contraction is thought
to be a critical component of the vagal response in patients
with neurocardiogenic syncope. Therefore, it is unclear
whether patients with ventricular dysfunction can develop
vasodepressor syncope, although they have an abnormal
vasodilatory response to a reduction in preload.(24) Heart
failure drug therapy, eg, ACE inhibitors and -blockers, can
further aggravate the abnormal baroreflexes in patients with a
cardiomyopathy by causing vasodilatation, volume depletion,
and sinus node dysfunction. For these reasons, an abnormal
head-up tilt table test alone should not lead to a diagnosis of
vasodepressor syncope in a patient with NIDCM.
Electrophysiological Study
Electrophysiological testing is frequently used to determine
whether there is an arrhythmic basis for syncope, but it is less
useful for patients with NIDCM than for patients with a prior
myocardial infarction.(25) Ventricular stimulation also ap-
pears to have a limited role in the evaluation of these patients
after an episode of syncope. A study of patients with
advanced heart failure and syncope that included a large
number of patients with NIDCM found that the 1-year risk of
sudden death was 45% regardless of the cause of synco-
pe.(26) These results suggest that electrophysiological testing
in patients with NIDCM and syncope has a low negative
predictive value. There is no consistent evidence to support
the use of noninvasive testing to further risk-stratify a patient
with unexplained syncope and a dilated cardiomyopathy.
NIDCM, Unexplained Syncope, and Negative
Electrophysiological Study
Data are limited with regard to the appropriate therapy for
patients with NIDCM and syncope when a complete evalua-
tion is unrevealing. There is no evidence to support the
empirical use of antiarrhythmic drugs in these patients.
Implantable defibrillator therapy, however, may be reason-
able. A study of 14 patients with NIDCM, unexplained
syncope, and a negative electrophysiological test who were
treated with an implantable defibrillator found that 50% of
the patients received appropriate defibrillator therapy during
2 years of follow-up.(27) Furthermore, recurrent syncope and
presyncope were due primarily to ventricular
tachyarrhythmias, and the incidence of appropriate shocks
was similar to that of patients with NIDCM and a history of
cardiac arrest.(27) A similar study found a high proportion of
appropriate defibrillator therapies in a group of patients with
NIDCM and syncope who had no inducible arrhythmias.(28)
At least 2 additional studies that reported the outcome of
patients with NIDCM treated with an implantable defibrilla-
tor for secondary prevention of sudden cardiac death included
patients who presented with syncope.(29,30) In 1 study, 10
patients presented with syncope resulting from ventricular
tachycardia.(29) In the other study, 6 of 49 patients presented
with syncope.(30) About half of the patients in each study
received an appropriate shock during follow-up.
Several recent large trials have demonstrated the efficacy
of defibrillator therapy in patients with advanced heart
disease without prior syncope. The SCD-HeFT trial included
a large number of patients with NIDCM and congestive heart
failure. This study demonstrated a survival advantage with
defibrillator therapy.(20) In the DEFINITE trial, which en-
rolled only patients with NIDCM, defibrillator therapy sig-
nificantly reduced the risk of sudden cardiac death and
demonstrated a nearly significant reduction in overall mor-
tality.(31) Because syncope probably further increases the
risk of sudden cardiac death in patients with NIDCM, ICD
therapy is appropriate in this setting.
Syncope in Other Forms of Structural Heart Disease
Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy is a relatively frequent (1 in
500 individuals), genetically determined myocardial disease
with a variable prognosis.(32–34) The diagnosis of hypertro-
phic cardiomyopathy is confirmed with echocardiography,
which demonstrates a hypertrophied, nondilated left ventricle
in the absence of secondary causes of hypertrophy. Although
the risk of sudden cardiac death was initially overestimated
because of referral bias, hypertrophic cardiomyopathy re-
mains an important cause of sudden death, particularly in
young patients. The annual risk of sudden death in unselected
patients with hypertrophic cardiomyopathy is estimated to be
0.6% to 1%.(33,34) There is often a striking discordance
between the risk of sudden cardiac death, echocardiographic
findings, and the presence of symptoms.
Syncope is a major risk factor for subsequent sudden
cardiac death in hypertrophic cardiomyopathy (relative risk
5), particularly if it is repetitive or occurs with exer-
tion.(32–34) However, in addition to self-terminating ventric-
ular arrhythmias, many other mechanisms can cause syncope
in hypertrophic cardiomyopathy, including supraventricular
arrhythmias, severe outflow-tract obstruction, bradyarrhyth-
mias, decreased blood pressure in response to exercise, and
neurocardiogenic syncope.(32) The presence or absence of
other sudden cardiac death risk factors such as family history
of sudden death, frequent nonsustained ventricular
tachycardia, or marked hypertrophy may help in the determi-
nation of risk. Most authorities agree that electrophysiologi-
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cal testing plays a minimal role in risk stratification. Specific
genetic mutations have been identified that are associated
with high risk of sudden cardiac death. However, the use of
genotyping to determine sudden cardiac death risk is not
readily available and is not routine.
Observational studies have demonstrated that implantable
defibrillator therapy is effective in high-risk patients with
hypertrophic cardiomyopathy.(35) Twelve percent of patients
with hypertrophic cardiomyopathy who received an implant-
able defibrillator for primary prevention of sudden cardiac
death received appropriate therapies during 3 years of follow-
up. The incidence of appropriate and inappropriate implant-
able defibrillator shocks was 40% and 25%, respectively, in
patients treated for secondary prevention.(35)
Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy
ARVD/C is characterized by ventricular tachycardia and
morphological abnormalities of the right ventricle caused by
myocyte replacement by adipose tissue or fibrosis.(36)
ARVD/C may be familial (30% to 50%), but sporadic forms
occur and may represent a different disease process. The
diagnosis of ARVD/C can be subtle, and the adoption of
consensus criteria based on structural, functional, and ECG
characteristics has been helpful.(37,38) Up to 20% of sudden
cardiac deaths in patients35 years of age may be secondary
to ARVD/C. Sudden cardiac death may be the first manifes-
tation of the disease process, but patients usually present with
premature ventricular beats, syncope, or sustained ventricular
tachycardia with a left bundle-branch block morphology.
Syncope is regarded as an ominous finding in ARVD/C.
The utility of electrophysiological testing in these patients is
not firmly established. Typically, sustained ventricular
tachycardia is induced in patients who have presented clini-
cally with ventricular tachycardia, but its role in risk stratifi-
cation is unclear. Several recent series have demonstrated the
efficacy of implantable defibrillator therapy in this group,
noting annual rates of appropriate implantable defibrillator
therapy of approximately 15% to 20%.(39,40)
Syncope Resulting From Inherited Cardiac Ion
Channel Abnormalities
Inherited cardiac ion channel abnormalities can cause syn-
cope and sudden death as a result of ventricular arrhythmias
in the absence of structural heart disease. The 2 most
prevalent are the LQTS and the Brugada syndrome. The
diagnosis of both conditions relies on a careful family history
and analysis of the ECG (Figures 2 and 3). Family screening
is important when an index patient is identified, although
sporadic cases also occur.
Long-QT Syndrome
LQTS is characterized by prolongation of the QT interval
with a QTc 450 ms. A genetic defect in either cardiac
potassium (LQT1 and LQT2) or sodium (LQT3) channels
results in delayed repolarization and QT prolongation.(41)
LQTS generally is inherited with an autosomal dominant
pattern variable penetrance. The risk of cardiac events de-
pends on the specific genetic defect, gender, and age.(42) The
most important nondemographic risk factor is the degree of
QT prolongation. The lifetime risks of syncope or aborted or
actual sudden death in LQTS patients with a QTc 440 ms,
460 to 500 ms, and 500 ms are approximately 5%, 20%,
and 50%, respectively. Syncope is an ominous finding and is
presumably secondary to an episode of torsade des pointes
polymorphic ventricular tachycardia that terminates sponta-
neously. Treatment options include -blockers and implant-
able defibrillators.(43) Other important interventions include
restriction of strenuous or competitive exercise, avoidance of
medicines that prolong the QT interval (a comprehensive
listing is available at www.QTdrugs.org), and family
screening.
Brugada Syndrome
The Brugada syndrome is a heritable disorder of the cardiac
sodium channel resulting in ST elevation in the anterior
precordial leads, ie, V1 and V2, and susceptibility to poly-
morphic ventricular tachycardia.(44) The distinctive ECG
pattern is diagnostic (Figure 2), although the ECG is often
dynamic. The diagnostic ECG findings may be intermittent,
change over time, or be present only after provocative
maneuvers, eg, procainamide infusion. Patients with Brugada
syndrome who present with syncope have a 2-year risk of
sudden cardiac death of approximately 30%(44); hence,
implantable defibrillator therapy typically is recommended.
Evaluation of the Pediatric Patient With Syncope
The differential diagnosis and evaluation of syncope in
pediatric patients are similar to those in adults. Because
Figure 2. Different patterns of QT prolon-
gation in LQTS. Morphology of the QT
segment and T wave may be different in
different genetic subsets of the LQTS,
although there is significant individual
variation. Reproduced with permission
from Moss et al.(64)
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underlying heart disease is less common in the young,
syncope in pediatric patients is generally benign. The goal of
the evaluation is to identify high-risk patients with underlying
heart disease, which may include identifiable genetic abnor-
malities such as the LQTS, Brugada syndrome, or hypertro-
phic cardiomyopathy. The evaluation of the pediatric patient
with syncope may extend to other family members when a
genetic condition is identified.
The evaluation of syncope in the absence of underlying
heart disease, ECG abnormalities, or positive family history
is limited in scope and often ends with the exclusion of
underlying heart disease. Syncope associated with high-
intensity physical activity is a typical presentation of hyper-
trophic cardiomyopathy or catecholaminergic polymorphic
ventricular tachycardia and generally is evaluated with an
echocardiogram and an exercise stress test.
Syncope in a pediatric patient with a normal ECG and
echocardiogram may be due to breathholding spells.(45,46)
Breathholding spells resulting from emotional upset have
been reported in 2% to 5% of well patients, and therapy is
rarely required.(46) Neurocardiogenic syncope in the healthy
child or adolescent is a common disturbance.
Bradycardia and Tachycardia
In pediatric patients, syncope caused by isolated bradycardia
is relatively uncommon. In children, resting bradycardia may
indicate drug ingestion, cardiac manifestations of anorexia
nervosa, or central nervous system trauma. Transient but
profound sinus pauses or sustained bradycardia may result in
syncope due to a neurocardiogenic reflex. Most symptoms
associated with sinus node dysfunction are due to an inade-
quate chronotropic response, but associated tachycardia
should be sought. Syncope is uncommon in patients with
first- and second-degree heart block, but the occurrence of
complete AV block is a Class I indication for permanent
pacing.(23) Tachycardia may cause syncope in the ostensibly
normal pediatric patient; palpitations are a usual accompany-
ing symptom, but other nonspecific symptoms such as light-
headedness, chest pain, dyspnea, pallor, or nausea may be
present.
Underlying Heart Disease
As in the adult patient, when underlying heart disease is
present, syncope is potentially life-threatening for pediatric
patients as compared with their normal counterparts.(47) The
evaluation of syncope in this setting requires an understand-
ing of the patient’s cardiac anatomy, surgical history, and
residual hemodynamic burden. Syncope resulting from hy-
percyanotic spells in children with untreated congenital heart
disease such as tetralogy of Fallot is uncommon and should
be considered an indication for surgical intervention. Com-
plete AV block or ventricular tachycardia may account for
syncope in patients with a history of surgery involving the
ventricle(s), eg, tetralogy of Fallot or a ventricular septal
defect. If ventricular tachycardia is suspected, then electro-
physiological testing may be helpful. Patients with sustained
ventricular tachycardia or symptomatic nonsustained ventric-
ular tachycardia should be treated.
Hypertrophic cardiomyopathy is the most common cause
of sudden cardiac death in adolescents.(48) Young age and
syncope are risk factors for sudden cardiac death among these
patients.(37,49,50) In pediatric patients with aortic stenosis,
syncope typically occurs with exercise and is an ominous
sign.(46) Syncope frequently is seen in children with primary
pulmonary hypertension. Near-syncope or syncope has been
reported as the presenting symptom in 13% of children with
idiopathic dilated cardiomyopathy.(51)
Coronary artery anomalies are present in approximately
1% of the population. Although most children and adoles-
cents with coronary artery anomalies are asymptomatic,
Figure 3. ECG changes in the Brugada
syndrome. ST elevation occurs in the
anterior precordial leads, leads V1 and
V2. Type 1 (coved) ECGs with 1 mV of
ST elevation have the most prognostic
significance. ECG recordings may
change over time, as in this example,
and serial ECGs may be important.
Reproduced with permission from Wilde
et al.(65)
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syncope or sudden cardiac death may be the presenting
symptom.(52,53) Patients are most at risk when an anoma-
lous coronary artery courses between the aorta and the
pulmonary artery trunk.
Special Considerations in the Elderly
The annual incidence of a fall in the elderly is 30%. Up to 30%
of falls in the elderly may be due to syncope.(54) The clinical
presentation of syncope in the elderly is often variable and
atypical. Marked clinical overlap exists between falls, orthostatic
hypotension, and dizzy spells, which may all present as synco-
pe.(54,55) Furthermore, syncope may be multifactorial in the
elderly patient. Special considerations in the evaluation of
syncope in the elderly include (1) age-related changes that
predispose the elderly to syncope; (2) varied clinical presentation
that includes falls, gait disorders, dizzy spells, and amnesia; (3)
drug interactions; and (4) multiple diseases.
Several age-related changes predispose the elderly to
syncope. These alterations include reductions in thirst, ability
to preserve sodium and water, baroreceptor response, and
heart rate response to orthostatic stress, as well as autonomic
dysfunction.(55,56) These physiological changes, in combi-
nation with the frequent use of multiple medications, are risk
factors for orthostatic intolerance and syncope.
Aging is associated with a variety of diseases, including
underlying heart disease, gait disorders, cardiovascular de-
conditioning, recurrent falls, and orthostatic hypotension. The
elderly often are treated with multiple medications, including
diuretics, -blockers, calcium antagonists, ACE inhibitors,
nitrates, antipsychotic agents, tricyclic antidepressants, anti-
histamines, dopamine agonists and antagonists, and narcotics,
all of which may precipitate syncope. Alcohol also may be a
contributing factor. The effects of these drugs and their
interactions are exacerbated in the elderly because of the loss
of peripheral autonomic tone that occurs with aging.(56)
Orthostatic hypotension is common in older patients and is the
cause of syncope in 6% to 33% of patients.(57) A common
clinical presentation of syncope in the elderly is postprandial
hypotension that is frequently confused with transient ischemic
attacks or seizures. Carotid sinus hypersensitivity is an under-
recognized cause of syncope in the elderly.(58) A recent report
suggests that 30% of unexplained syncope in the elderly is due
to carotid sinus hypersensitivity, although pacing may not
prevent syncope.(59) Neurally mediated causes remain a fre-
quent mechanism of syncope in the elderly and may be under-
estimated because of an atypical presentation. Cardiovascular
medications may be responsible for almost half of these
episodes.
Elderly patients may present with recurrent falls resulting
from syncope. Gait disorders secondary to central nervous
system alterations may be associated with orthostatic hypo-
tension and other chronic autonomic disorders. Unexplained
syncope may be the first manifestation of degenerative
disorders such as Parkinson’s disease.(56,60) Classic clinical
features of neurally mediated causes of syncope, including
typical pre-episode and postepisode symptoms, often are
absent in older patients.(11,56) Furthermore, complete amne-
sia is present in up to 40% of elderly patients with
syncope.(61)
As with other patients with syncope, the goal of the
diagnostic evaluation in the elderly is to exclude life-
threatening illnesses and to prevent recurrent falls. Orthostat-
ic blood pressure and heart rate measurements should be
obtained.
The treatment of syncope is directed at its cause. In the
elderly, multiple origins of syncope frequently coexist and
need to be addressed. Particular emphasis should be given to
the impact of polypharmacy, orthostatic intolerance, auto-
nomic dysfunction, and carotid sinus hypersensitivity.
Neurological Evaluation
Neurological causes should be considered in patients with syncope,
although syncope is an unusual manifestation of neurological
processes. Neurological causes of syncope should be pursued only
if suggested by the history or physical examination.
Cardiac causes of syncope can be accompanied by upward
gaze deviation, asynchronous myoclonic jerks, and brief
automatisms that result from global cerebral hypoperfusion
and are not an indication for a neurological evaluation.
Cerebrovascular disease can cause syncope in the presence of
severe bilateral carotid or basilar artery disease, but syncope
in these settings rarely occurs in the absence of other focal
neurological signs or symptoms. Syncope in the supine
position, preceded by an aura, or followed by confusion or
amnesia is likely caused by a neurological disorder. Focal
neurological signs such as diplopia, limb weakness, sensory
deficits, or speech difficulties indicate an abnormality in a
particular brain area, are usually caused by a seizure, and are
an indication for a neurological evaluation.(62,63)
Neurological disorders that cause syncope typically result
in orthostatic hypotension from dysautonomia, and they can
be suspected by the history, screening neurological examina-
tion, and bedside testing of orthostatic vital signs. Orthostatic
hypotension can be induced by tricyclic antidepressants,
nitrates, and antiparkinsonian medications; neurodegenera-
tive disorders of the central nervous system such as Parkin-
son’s disease; or a peripheral autonomic neuropathy such as
diabetes mellitus. Autonomic testing to confirm the presence
of a dysautonomia, distinguish central from peripheral
causes, and guide patient management includes tilt table
testing, cardiac responses to deep breathing and the Valsalva
maneuver, and sweat testing. Disorders that increase intracra-
nial pressure, eg, subarachnoid hemorrhage or rarely brain
tumors, can result in true syncope. The neurological basis of
these disorders is usually obvious and associated with head-
ache, meningismus, and/or other focal neurological findings.
Seizure disorders are the most common neurological cause
of episodic unresponsiveness. Seizure disorders can be con-
firmed by an electroencephalogram, although repeated stud-
ies, prolonged electroencephalographic monitoring, or a
sleep-deprived electroencephalogram may be necessary.
Cardiac involvement is frequent in neuromuscular dis-
eases, eg, Duchenne dystrophy. As a result of cardiac in-
volvement, these patients may develop cardiomyopathy,
complete AV block, ventricular tachycardia, or ventricular
fibrillation. Evaluation of syncope in the setting of a neuro-
muscular disease includes an ECG, an echocardiogram, and
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an assessment for cardiac ischemia. Treatment may include
pacemaker or implantable defibrillator therapy.(21)
When a neurological basis of syncope is suspected, imag-
ing of the brain with either CT or MRI is indicated. If
cerebrovascular disease is suspected, imaging of the extracra-
nial and intracranial carotid arteries is appropriate.
Conclusions
Syncope can be a precursor to sudden death, particularly in
patients with underlying heart disease. Most importantly, the
evaluation of syncope includes an assessment for structural
heart disease and ischemia. Less common causes of syncope
that are associated with sudden death should be excluded and
include Wolff-Parkinson-White syndrome and inherited car-
diac ion channel abnormalities, eg, LQTS. When underlying
heart disease is identified, the evaluation and treatment are
generally 2 pronged. First, the underlying heart disease, with
or without ischemia, and its possible contribution to the
episode of syncope must be addressed. Second, a primary
arrhythmia evaluation, with ventricular tachycardia or ven-
tricular fibrillation in mind, should be pursued. A specific
diagnosis should be obtained, particularly in high-risk pa-
tients, thus allowing appropriate and potentially life-saving
therapy.
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